Given the evidence from the canakinumab trial, we propose that the reduced plaque burden observed after IL1RAP blockade is at least in part mediated by limiting IL-1 signalling but that IL-33 and IL-36 signalling may also act to aggravate atherosclerosis by promoting chemokine release. Here, IL33 is linked to atherosclerosis.